The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Dec. 8, 9:15 AM

Slide #3. NeuroDerm Ltd. Secondary Offering

Company: NeuroDerm Ltd. (NASDAQ:NDRM)
Date announced: 12/6/2016
Shares Offered: 4,000,000
Date of Pricing: 12/7/2016
Price Per Share: $18.75
Secondary Offering Details: NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of a follow-on offering of its ordinary shares. All of the ordinary shares will be offered by NeuroDerm. The company expects to use the net proceeds of the offering to fund ongoing and planned clinical trials for its product candidates and the development of related devices and for research and development of other product candidates and general corporate purposes. -updated 12/7- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of a follow-on offering of 4,000,000 shares of its ordinary shares at a price to the public of $18.75 per share. All of the ordinary shares are being offered by NeuroDerm. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares at the public offering price. NeuroDerm anticipates the total gross proceeds from the offering before underwriting discounts and commissions and other offering expenses will be approximately $75.0 million. The offering is expected to close on or about December 12, 2016, subject to customary closing conditions. The company expects to use the net proceeds of the offering to fund ongoing and planned clinical trials for its product candidates and the development of related devices and for research and development of other product candidates and general corporate purposes.

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system, or CNS, disorders through proprietary formulations based on existing drugs. Co. is developing a pipeline of product candidates for the growing population of moderate and severe Parkinson's disease patients. Co. is also developing a product candidate for patients suffering from cognition disorders associated with CNS diseases. These diseases include Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder, or ADD/ADHD, Alzheimer's disease and schizophrenia.
Open the NDRM Page at The Online Investor »

Company Name:  NeuroDerm Ltd.
Website:  www.neuroderm.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding NDRM:  6
Total Market Value Held by ETFs:  $7.63M
Total Market Capitalization:  $425.00M
% of Market Cap. Held by ETFs:  1.79%
 

Open the NDRM Page at The Online Investor (in a new window) »

December 8, 2016    9:15 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.80 out of 4)
82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.